Cargando…
British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
From 1979-1983, 299 patients with stage III or IV Hodgkin's disease (HD) were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran substituted for mustine). Two hundred and ninety patients were evaluable. There was no statistically...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972355/ https://www.ncbi.nlm.nih.gov/pubmed/2021542 |
_version_ | 1782135011132047360 |
---|---|
author | Hancock, B. W. Vaughan Hudson, G. Vaughan Hudson, B. Haybittle, J. L. Bennett, M. H. MacLennan, K. A. Jelliffe, A. M. |
author_facet | Hancock, B. W. Vaughan Hudson, G. Vaughan Hudson, B. Haybittle, J. L. Bennett, M. H. MacLennan, K. A. Jelliffe, A. M. |
author_sort | Hancock, B. W. |
collection | PubMed |
description | From 1979-1983, 299 patients with stage III or IV Hodgkin's disease (HD) were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran substituted for mustine). Two hundred and ninety patients were evaluable. There was no statistically significant difference between the complete remission (CR) rates (63% for MOPP, 57% for LOPP), percentage of patients remaining disease free at 5 years (38% for MOPP, 35% for LOPP) and overall survival at 5 years (65% for MOPP, 64% for LOPP). On multivariate analysis younger age, grade I histopathology, absence of systemic symptoms, and normal albumin level were favourable prognostic factors for survival. Acute toxicity in the form of nausea/vomiting, myelosuppression, and phlebitis were less with LOPP than MOPP. Deaths in both groups were usually due to disseminated Hodgkin's disease; there were no infective deaths in the absence of Hodgkin's disease. Second malignancies occurred in six patients treated with MOPP--three acute myeloid leukaemia (AML), one non-Hodgkin's lymphoma (NHL), two carcinomas (Ca); with LOPP, four second malignancies occurred (one AML, one NHL, two Ca). These long term results confirm that LOPP is as effective as MOPP, and less toxic, in the treatment of advanced Hodgkin's disease. |
format | Text |
id | pubmed-1972355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1991 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19723552009-09-10 British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. Hancock, B. W. Vaughan Hudson, G. Vaughan Hudson, B. Haybittle, J. L. Bennett, M. H. MacLennan, K. A. Jelliffe, A. M. Br J Cancer Research Article From 1979-1983, 299 patients with stage III or IV Hodgkin's disease (HD) were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran substituted for mustine). Two hundred and ninety patients were evaluable. There was no statistically significant difference between the complete remission (CR) rates (63% for MOPP, 57% for LOPP), percentage of patients remaining disease free at 5 years (38% for MOPP, 35% for LOPP) and overall survival at 5 years (65% for MOPP, 64% for LOPP). On multivariate analysis younger age, grade I histopathology, absence of systemic symptoms, and normal albumin level were favourable prognostic factors for survival. Acute toxicity in the form of nausea/vomiting, myelosuppression, and phlebitis were less with LOPP than MOPP. Deaths in both groups were usually due to disseminated Hodgkin's disease; there were no infective deaths in the absence of Hodgkin's disease. Second malignancies occurred in six patients treated with MOPP--three acute myeloid leukaemia (AML), one non-Hodgkin's lymphoma (NHL), two carcinomas (Ca); with LOPP, four second malignancies occurred (one AML, one NHL, two Ca). These long term results confirm that LOPP is as effective as MOPP, and less toxic, in the treatment of advanced Hodgkin's disease. Nature Publishing Group 1991-04 /pmc/articles/PMC1972355/ /pubmed/2021542 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Hancock, B. W. Vaughan Hudson, G. Vaughan Hudson, B. Haybittle, J. L. Bennett, M. H. MacLennan, K. A. Jelliffe, A. M. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. |
title | British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. |
title_full | British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. |
title_fullStr | British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. |
title_full_unstemmed | British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. |
title_short | British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. |
title_sort | british national lymphoma investigation randomised study of mopp (mustine, oncovin, procarbazine, prednisolone) against lopp (leukeran substituted for mustine) in advanced hodgkin's disease--long term results. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972355/ https://www.ncbi.nlm.nih.gov/pubmed/2021542 |
work_keys_str_mv | AT hancockbw britishnationallymphomainvestigationrandomisedstudyofmoppmustineoncovinprocarbazineprednisoloneagainstloppleukeransubstitutedformustineinadvancedhodgkinsdiseaselongtermresults AT vaughanhudsong britishnationallymphomainvestigationrandomisedstudyofmoppmustineoncovinprocarbazineprednisoloneagainstloppleukeransubstitutedformustineinadvancedhodgkinsdiseaselongtermresults AT vaughanhudsonb britishnationallymphomainvestigationrandomisedstudyofmoppmustineoncovinprocarbazineprednisoloneagainstloppleukeransubstitutedformustineinadvancedhodgkinsdiseaselongtermresults AT haybittlejl britishnationallymphomainvestigationrandomisedstudyofmoppmustineoncovinprocarbazineprednisoloneagainstloppleukeransubstitutedformustineinadvancedhodgkinsdiseaselongtermresults AT bennettmh britishnationallymphomainvestigationrandomisedstudyofmoppmustineoncovinprocarbazineprednisoloneagainstloppleukeransubstitutedformustineinadvancedhodgkinsdiseaselongtermresults AT maclennanka britishnationallymphomainvestigationrandomisedstudyofmoppmustineoncovinprocarbazineprednisoloneagainstloppleukeransubstitutedformustineinadvancedhodgkinsdiseaselongtermresults AT jelliffeam britishnationallymphomainvestigationrandomisedstudyofmoppmustineoncovinprocarbazineprednisoloneagainstloppleukeransubstitutedformustineinadvancedhodgkinsdiseaselongtermresults |